[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100550671":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":18,"centralContacts":19,"locations":25,"responsibleParty":85,"collaborators":18,"id":87,"slug":88,"hasResults":89,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":18,"eligibilityCriteria":93,"healthyVolunteers":89,"sex":94,"minAge":95,"maxAge":18,"enrollmentInfo":96,"targetDuration":18,"studyType":99,"phases":100,"briefSummary":102,"conditions":103,"keywords":105,"overallStatus":28,"whyStopped":18,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":127},{"fullName":5,"class":6},"SURGE Therapeutics","INDUSTRY",[8],{"label":9,"type":10,"description":9,"interventionNames":11},"STM-416p","EXPERIMENTAL",[12],"Drug: STM-416p",[14],{"type":15,"name":9,"description":16,"armGroupLabels":17,"otherNames":18},"DRUG","STM-416p monotherapy",[9],null,[20],{"name":21,"role":22,"phone":23,"phoneExt":18,"email":24},"Kayti Aviano","CONTACT","781-605-8632","kayti@surgetx.com",[26,47,64,77],{"facility":27,"status":28,"city":29,"state":30,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"Arizona Urology Specialists","RECRUITING","Tucson","Arizona","85715","United States","US",{"type":35,"coordinates":36},"Point",[37,38],-110.92648,32.22174,{"lat":38,"lon":37},[41,44],{"name":42,"role":22,"phone":18,"phoneExt":18,"email":43},"Jasmine Simpson","JSIMPSON@arizonauro.com",{"name":45,"role":46,"phone":18,"phoneExt":18,"email":18},"Susan Kalota, MD","PRINCIPAL_INVESTIGATOR",{"facility":48,"status":28,"city":49,"state":50,"zip":51,"country":32,"countryCode":33,"cosmosGeoPoint":52,"geoPoint":56,"contacts":57},"University of Florida","Gainesville","Florida","32608",{"type":35,"coordinates":53},[54,55],-82.32483,29.65163,{"lat":55,"lon":54},[58,60,62],{"name":59,"role":22,"phone":18,"phoneExt":18,"email":18},"Danielle Geckler",{"name":18,"role":22,"phone":18,"phoneExt":18,"email":61},"d.geckler@ufl.edu",{"name":63,"role":46,"phone":18,"phoneExt":18,"email":18},"Paul Crispen, MD",{"facility":65,"status":28,"city":66,"state":67,"zip":68,"country":69,"countryCode":70,"cosmosGeoPoint":18,"geoPoint":18,"contacts":71},"Australian Prostate Center","Melbourne N.","Victoria","3051","Australia","AU",[72,75],{"name":73,"role":22,"phone":18,"phoneExt":18,"email":74},"Dina Bushell","dina.bushell@apcr.org.au",{"name":76,"role":46,"phone":18,"phoneExt":18,"email":18},"Phil Dundee, MD",{"facility":78,"status":28,"city":66,"state":67,"zip":68,"country":69,"countryCode":70,"cosmosGeoPoint":18,"geoPoint":18,"contacts":79},"Epworth HealthCare",[80,83],{"name":81,"role":22,"phone":18,"phoneExt":18,"email":82},"Daniel Shokouhi","ctc-urorenal@epworth.org.au",{"name":84,"role":46,"phone":18,"phoneExt":18,"email":18},"Nathan Lawrentschuk, Prof",{"type":86,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR","100550671","phase-1-study-of-stm-416p-administered-to-patients-undergoing-radical-prostatectomy-100550671",false,"NCT06450106","Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy","A Phase 1 Dose Escalation Study of STM-416p Administered Intraoperatively to Patients Undergoing Radical Prostatectomy","Inclusion Criteria:\n\n1. Males aged 18 years or older at time of informed consent.\n2. Have a histologically confirmed diagnosis of prostate cancer, and are scheduled to undergo radical prostatectomy within 28 days of screening.\n3. Grade Group 2-5.\n4. Eastern Cooperative Oncology Group (ECOG) Performance Status ≤2 at Screening.\n5. Have adequate organ and bone marrow function at screening.\n6. Able to understand and be willing to sign an Institutional Review Board\u002FEthics Committee-approved written informed consent document\n\nExclusion Criteria:\n\n1. Have an invasive malignancy, other than the disease under study.\n2. Anticipated to require the use of a drain after radical prostatectomy.\n3. Received any other anticancer therapy (e.g., including but not limited to chemotherapy, biologic therapy, immunotherapy, targeted therapy, endocrine therapy, radiation therapy, intravesical therapy ) within 28 days.\n4. History of allergic reactions attributed to compounds of similar chemical or biologic composition as those used in the STM-416p formulation including poloxamer 407 and sodium hyaluronate.\n5. History of allogeneic organ transplant.\n6. History of primary immunodeficiency.\n7. QTc interval \\>470 msec at Screening.","MALE","18 Years",{"count":97,"type":98},18,"ESTIMATED","INTERVENTIONAL",[101],"PHASE1","A Study of STM-416p Administered Intraoperatively to Patients Undergoing Radical Prostatectomy",[104],"Prostate Cancer",[106,107,108,109,110,111,112,113,114,9,115,116,117],"Intraoperative","Dose escalation","Open-label","STM-416","Resiquimod","Toll-like receptor 7\u002F8","Radical prostatectomy","Robotic prostatectomy","Immunotherapy","PSA","R848","Hydrogel","2026-02-17",{"date":120,"type":121},"2026-02-19","ACTUAL",{"date":123,"type":121},"2025-05-08",{"date":125,"type":98},"2026-12",{"name":5,"class":6},4]